ADAM-19 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAM-19 (UniProt Q9H013), HEK293-expressed. Used in metalloprotease activity assays, neuregulin substrate cleavage studies, inhibitor profiling, and antibody validation.
Expression system
HEK293
Cat. #
REC-ADAM19

In stock

SKU
REC-ADAM19
$498.00

Target Overview

ADAM-19 (Disintegrin and metalloproteinase domain-containing protein 19; UniProt Q9H013) is a membrane-anchored metalloprotease of the ADAM family encoded by the ADAM19 gene. The full-length human sequence spans 955 amino acids and includes a prodomain, a zinc-dependent metalloprotease domain, a disintegrin domain, a cysteine-rich region, an EGF-like domain, a transmembrane segment, and a cytoplasmic tail. This recombinant form is produced in HEK293 mammalian cells, an expression system that supports the glycosylation and disulfide-bond formation characteristic of the native protein — features that are relevant when using the protein as a functional enzyme or as an immunological standard. ADAM-19 participates in the proteolytic processing of beta-type neuregulin isoforms, placing it at the intersection of ectodomain shedding and glial cell signalling. It also cleaves alpha-2 macroglobulin and has been implicated by similarity in osteoblast differentiation and activity. Researchers use this recombinant in several contexts: (1) metalloprotease activity assays measuring cleavage of neuregulin-derived or generic peptide substrates; (2) inhibitor IC50 determinations against the ADAM-19 catalytic domain; (3) substrate identification experiments using mass spectrometry; (4) surface plasmon resonance or biolayer interferometry binding studies with candidate inhibitors or binding partners; and (5) antibody validation, where the recombinant serves as a defined positive-control antigen. Researchers pairing this recombinant with an anti-ADAM-19 antibody for Western blot or IHC validation can cross-reference the matched Triple Point Biologics antibody (catalog RP-ADAM19). Species reactivity against human sequence is validated; cross-reactivity with mouse, rat, monkey, and dog orthologues is predicted based on sequence conservation.

Background

ADAM-19 (also known as Meltrin-beta and MADDAM) belongs to the ADAM (A Disintegrin And Metalloproteinase) family of zinc-dependent sheddases, a group of transmembrane proteases responsible for regulated ectodomain shedding of growth factors, cytokines, and receptors. Within this family, ADAM-19 has been characterised by its role in processing beta-type neuregulin isoforms, substrates that are central to neurogenesis and synaptogenesis, and by its capacity to cleave the broad-spectrum protease inhibitor alpha-2 macroglobulin. These activities position ADAM-19 as a regulatory node connecting extracellular matrix remodelling, growth factor signalling, and cell differentiation. Published research has investigated ADAM-19 across several physiologically and pathologically relevant contexts. In connective-tissue biology, Smyth et al. (2025) demonstrated that microRNA-29b regulates ADAM12 and ADAM19 expression in lamina cribrosa cells, with downstream effects on extracellular matrix composition — identifying ADAM-19 as a miRNA-regulated remodelling effector in ocular connective tissue (PMID 40982030). This type of finding has prompted researchers to use recombinant ADAM-19 as a tool for characterising miRNA-driven changes in metalloprotease activity. In reproductive biology, ADAM-19 has been studied as a target of miRNA-150-5p in chorionic tissue, where its regulation has been associated with preterm labour pathophysiology (Wang et al., 2025; PMID 40658522). In the context of peritoneal biology, Xu et al. (2026) reported that ADAM-19 participates in peritoneal fibrosis through modulation of M2 macrophage polarisation in peritoneal dialysis patients, characterising it as a component of the fibrotic signalling axis (PMID 42069851). ADAM-19 has also appeared in multi-omics profiling of dendritic cell activation in rheumatoid arthritis, where TNF stimulation modulates its expression (Alshevskaya et al., 2025; PMID 40649852), and in cardiac remodelling studies examining atrial fibrillation after myocardial infarction (Yang et al., 2025; PMID 41063651). Across these research areas, recombinant ADAM-19 has utility as an activity standard, a substrate in inhibitor-screening cascades, and a well-characterised antigen for validating detection reagents. Researchers selecting recombinant ADAM-19 for antibody validation studies are encouraged to consult the matched Triple Point Biologics anti-ADAM-19 antibody (RP-ADAM19), validated for Western blot against human targets, with predicted cross-reactivity for mouse and rat. Triple Point Biologics has produced proteinase and inhibitor antibodies since 1994, and this recombinant is manufactured to be consistent with those detection reagents.

Applications

  • Metalloprotease activity assay measuring cleavage of neuregulin-derived peptide substrates
  • Inhibitor IC50 determination against the ADAM-19 catalytic/disintegrin domain
  • Antibody validation positive control for Western blot using matched antibody RP-ADAM19
  • Substrate identification by mass spectrometry (ectodomain shedding substrate profiling)
  • Surface plasmon resonance or biolayer interferometry binding studies with candidate small-molecule or protein inhibitors
  • miRNA functional-rescue assay: recombinant ADAM-19 as activity readout following miR-29b or miR-150-5p transfection
  • Macrophage polarisation co-culture experiments requiring exogenous ADAM-19 protein as stimulant or control
  • Extracellular matrix remodelling assays in fibrosis or connective-tissue cell models

References

  1. Xu K et al. ADAM19 participated in peritoneal fibrosis by regulating M2 macrophage polarization in peritoneal dialysis patients. Sci Rep. 2026. doi:10.1038/s41598-026-51347-8. PMID: 42069851.
  2. Yang H et al. Low-intensity pulsed ultrasound attenuates atrial remodelling and atrial fibrillation after myocardial infarction: an experimental pre-clinical study. Europace. 2025. doi:10.1093/europace/euaf258. PMID: 41063651.
  3. Smyth A et al. MicroRNA-29b targets ADAM12 and 19 to regulate the extracellular matrix in lamina cribrosa cells. Cell Tissue Res. 2025. doi:10.1007/s00441-025-04006-9. PMID: 40982030.
  4. Wang N et al. Cell-free miRNA-150-5p serves as a biomarker and regulator of PROM-related preterm labor by targeting chorionic ADAM19. Am J Physiol Endocrinol Metab. 2025. doi:10.1152/ajpendo.00045.2025. PMID: 40658522.
  5. Alshevskaya A et al. Molecular Signatures of Dendritic Cell Activation upon TNF Stimulation: A Multi-Omics Study in Rheumatoid Arthritis. Int J Mol Sci. 2025. doi:10.3390/ijms26136071. PMID: 40649852.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type I transmembrane; cell surface; Golgi → endosomes

Frequently Asked Questions

What molecular weight band should I expect for recombinant ADAM-19 on SDS-PAGE or Western blot?

The full-length human ADAM-19 protein (UniProt Q9H013) has a predicted molecular weight of ~109 kDa from its 955-amino-acid sequence, but the mature processed form — lacking the signal peptide and prodomain — typically runs at approximately 85–95 kDa under reducing SDS-PAGE conditions. Glycosylation from the HEK293 expression system adds heterogeneous mass, so expect a diffuse band rather than a sharp single band. Under non-reducing conditions, disulfide-linked species may shift the apparent MW further. Confirm identity with matched antibody RP-ADAM19 (/anti-adam-19-rabbit-polyclonal-antibody).

Which processing form of ADAM-19 is this recombinant — prodomain-intact zymogen or mature active enzyme?

This recombinant is produced as an active enzyme: the prodomain has been removed, leaving the mature metalloprotease, disintegrin, cysteine-rich, and EGF-like ectodomain region. The zinc-dependent catalytic domain is therefore exposed and enzymatically competent without any additional activation step. If your assay requires a zymogen control, note that this preparation is not suitable for that purpose. The HEK293 expression system ensures proper disulfide-bond formation within the cysteine-rich domain, which is important for ectodomain shedding activity against neuregulin substrates.

What substrates does ADAM-19 cleave and what peptide substrate can I use in a fluorescent activity assay?

ADAM-19 cleaves the ectodomains of beta-type neuregulin isoforms (e.g., NRG-1β) and has documented activity against alpha-2 macroglobulin. For a fluorescent activity assay, the generic ADAM-family quenched fluorescent substrate Mca-KPLGL-Dpa-AR-NH2 (or the closely related Mca-PLAQAV-Dpa-RSSSR-NH2) is commonly used and provides measurable signal with ADAM family metalloproteases. Run the reaction in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2 at 37°C. Validate substrate cleavage by running a no-enzyme control and a EDTA-inhibited control (10 mM EDTA) in parallel to confirm zinc-dependence.

What buffer conditions and starting enzyme concentration should I use for an ADAM-19 activity assay?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol — is compatible with direct use in activity assays; dilute into the same buffer (minus glycerol if signal interference is a concern above 0.5%). For initial titration, start at 50–200 nM enzyme with 10–50 µM fluorescent substrate. Include 0.05% Brij-35 or 0.1% BSA to minimize non-specific surface adsorption at these concentrations. Glycerol carry-over above 1% final concentration can modestly reduce kcat; keep dilutions ≥1:10 from stock to avoid this effect.

How do I set up an IC50 inhibition assay with recombinant ADAM-19 and a test compound?

Use 50–100 nM ADAM-19 with substrate at or near Km (empirically determined per fluorescent substrate used, typically 10–30 µM for Mca-peptides). Pre-incubate enzyme with inhibitor for 30 minutes at 37°C before adding substrate — ADAM metalloprotease active sites can be slow-binding targets. EDTA (10 mM) and marimastat (broad-spectrum hydroxamate, 1 µM) serve as positive inhibition controls. Run each inhibitor concentration in triplicate and fit to a four-parameter logistic curve. Purity >90% by SDS-PAGE ensures that IC50 values are not artifactually elevated by inactive protein.

Can I use REC-ADAM19 as a positive control for Western blot with the matched antibody RP-ADAM19?

Yes — this is one of the primary use cases for pairing REC-ADAM19 with RP-ADAM19 (/anti-adam-19-rabbit-polyclonal-antibody). Load 25–100 ng of recombinant protein per lane alongside your cell lysate samples. At 25 ng you should see a clear band at ~85–95 kDa under reducing conditions that comigrates with endogenous ADAM-19 in positive-control cell lines. RP-ADAM19 is validated for Western blot with this recombinant in-house, so it provides a definitive size and signal reference for antibody titration experiments and lot-to-lot consistency checks.

How much recombinant ADAM-19 should I load per lane to validate antibody RP-ADAM19 on Western blot?

For a standard antibody validation Western blot, a two-fold dilution series of 10 ng, 25 ng, 50 ng, and 100 ng per lane works well. This range spans the linear detection window for most HRP-conjugated secondaries and allows you to confirm both sensitivity and specificity of RP-ADAM19. Use reducing sample buffer; the disulfide-linked ectodomain will partially shift under non-reducing conditions, which can complicate band interpretation during validation. Run alongside a lysate lane so you can confirm matched migration of the endogenous and recombinant bands.

How should I store and handle recombinant ADAM-19 to maintain activity after receipt?

Upon receipt, REC-ADAM19 is shipped on dry ice in single-use aliquots in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol. Store at -20°C immediately; avoid repeated freeze-thaw cycles, which denature the zinc-binding active site and degrade disulfide-integrity in the cysteine-rich domain. For working dilutions, prepare in the same buffer supplemented with 0.1% BSA to stabilize at low concentrations (below ~10 nM). Diluted working stocks are stable for up to 24 hours at 4°C. Do not store diluted enzyme at -20°C — the reduced glycerol concentration provides insufficient cryoprotection.

Validation imagery coming soon

Western blot validation figures for REC-ADAM19 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →